The shorting pieceThere are two parts to this for those wondering what role the short positions have on share valuation. We can find the volume of shares "borrowed" and what we don't see is the valuation each share was at, at the time of borrowing. Pushing share valuation to $2.80+ then borrowing at that value meant that losses because you borrowed at $.30 and had to cover at $.90, could be gained back in the difference between today's $1.30 and that historic high.
I would not speculate on how many shorters are borrowing at $1.30. If they are, they are betting that the science will collapse. After reading the MDA, that would seem to be a high risk bet. We'll know more about the change in the short position volume in the coming days.
As the MDA indicated, there are two shorter term milestones that will affect share valuation: results from more Chicago study enrolees, and the results of the anti-rejection therapies work. I think how that plays out for hemophilia patients could be good for them, and investors.
Lastly, to those who felt the loss of a friend who was an avid defender of SVA, condolences. "The independent guy prevails" is not always the Hollywood ending for all. Just the same, we certainly have someone looking down on all this hoping we are keeping our powder and shyte together, as the doubters have their day in court.
DF